These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9559396)

  • 1. Fluoroquinolones: a new treatment for tuberculosis?
    Gillespie SH; Kennedy N
    Int J Tuberc Lung Dis; 1998 Apr; 2(4):265-71. PubMed ID: 9559396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rapid development of fluoroquinolone resistance in M. tuberculosis.
    Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR
    N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
    Gumbo T; Louie A; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
    Lu T; Drlica K
    J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of new quinolones as antituberculosis drugs].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 1999 Jan; 74(1):71-5. PubMed ID: 10067058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinolones for the treatment and prophylaxis of tuberculosis.
    Kaplan JA; Krieff DM
    Ann Pharmacother; 1996 Sep; 30(9):1020-2. PubMed ID: 8876865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [View of development of fluoroquinolones].
    Namba K
    Kekkaku; 1999 Jan; 74(1):47-52. PubMed ID: 10067055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.
    Ginsburg AS; Hooper N; Parrish N; Dooley KE; Dorman SE; Booth J; Diener-West M; Merz WG; Bishai WR; Sterling TR
    Clin Infect Dis; 2003 Dec; 37(11):1448-52. PubMed ID: 14614666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Maxaquin in the combined treatment of tuberculosis].
    Sokolova GB; Mozhokina GN; Kunichan AD; Elistratova NA; Perel'man MI
    Probl Tuberk; 2000; (5):35-9. PubMed ID: 11077850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens].
    Mar'iandyshev AO; Klinberg NM; Shonbina AI; Moroz MI
    Probl Tuberk; 1997; (4):19-21. PubMed ID: 9333808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada.
    Bozeman L; Burman W; Metchock B; Welch L; Weiner M;
    Clin Infect Dis; 2005 Feb; 40(3):386-91. PubMed ID: 15668861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enhancement of the activity of antitubercular agents with other antimicrobial agents].
    Vinogradova TI
    Probl Tuberk; 1994; (3):59-62. PubMed ID: 7937678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-resistant Mycobacterium tuberculosis strains in tuberculosis inpatients in Bangui, Central African Republic.
    Garin B; Di Costanzo B; Kassa Kelembho E; Legot B; Guerin D; Ouapou-Lena F; Vohito MD; Vincent V; Mathiot C
    AIDS; 1995 Feb; 9(2):213-4. PubMed ID: 7718200
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS].
    Pulido F; Iribarren JA; Kindelan JM; Moreno S
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():20-8. PubMed ID: 9859616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.